A Single-centre, Placebo- and Standard-care-controlled, Double-blind, Randomised Trial to Investigate the Efficacy of Eight Doses of RN1003 in the Reduction of Scarring From the Approximated Wound Margins of Incisional Wounds

NCT00984646 Phase 2 COMPLETED

The purpose of this study was to investigate the scar-reducing properties of eight doses of intradermal Prevascar (IL-10).

Details

Lead sponsor	Renovo
Phase	Phase 2
Status	COMPLETED
Enrolment	175
Start date	2005-04
Completion	2006-11

Conditions

• Cicatrix
• Wound Healing

Interventions

• Prevascar
• Prevascar
• Prevascar
• Prevascar
• Prevascar
• Prevascar
• Prevascar
• Prevascar
• Placebo

Primary outcomes

• To establish which of eight intradermal doses of RN1003 has the greatest scar-reducing properties, compared with Placebo and Standard Care. — 12 months

Countries

United Kingdom